Telix Pharmaceuticals - ADR Share Price Today

Telix reaffirms FY26 revenue guidance above $1B, tracks upper end

Reaffirmed FY26 revenue and other income guidance above $1 billion. Tracking toward upper end of $950M-$970M revenue guidance range. Revised R&D expenditure guidance to $240M-$260M. Q3FY26 group revenue rose 19% YoY to $245 million.

Telix partners with Ekalia for US astatine-211 supply

Telix enters collaboration with Ekalia for dedicated US astatine-211 supply. Secures priority access for TLX102-Tx glioblastoma and leptomeningeal disease candidates. First IBA alpha-beam cyclotron to be installed at Telix's RLS site near Philadelphia. Framework allows evaluation of additional installations as demand develops. Supports third-party academic and industry programs alongside internal pipeline.

Telix secures FDA Fast Track designation for BiPASS prostate cancer program

FDA grants Fast Track designation to Telix's BiPASS program. Designation targets pre-biopsy prostate cancer imaging. Status aims to expedite drug development and review.

Telix signs US$1.65 billion deal to acquire ITM Isotope

Telix acquires ITM Isotope for US$1.65bn upfront, creating a vertically integrated radiopharma leader. Deal includes US$1.25bn in shares, US$302m assumed debt, and up to US$700m in contingent milestones. Combined pro forma 2026 revenue projected to exceed US$1.3bn, with positive EBITDA expected from 2027. Telix shares fell nearly 10% following the announcement, closing at US$11.35. ITM-11 recently received an FDA CRL for GEP-NETs due to third-party manufacturing issues.

FDA approves Telix Pixclara as first US glioma imaging drug

FDA approves Pixclara as first US PET drug for glioma imaging. Drug differentiates recurrent glioma from treatment-related changes. Shares rose 7.44% to $12.13, nearing 52-week high of $12.48. Phase 3 study ongoing for potential brain metastases indication.

Telix completes Phase 3 BiPASS enrollment, aligns with FDA on NDA pathway

Telix completed enrollment of 350 patients in the Phase 3 BiPASS study across the US and Australia. The company aligned with the FDA on an NDA pathway to support new product reimbursement for PSMA-PET imaging. BiPASS evaluates ^68Ga-PSMA-11 PET combined with MRI for detecting prostate cancer prior to biopsy. Previous studies showed combining PET with MRI can reduce unnecessary biopsies by almost 50 percent. Up to 75% of the three million annual global prostate biopsies are found to be negative.